<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34090980</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1916-7075</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Canadian journal of cardiology</Title><ISOAbbreviation>Can J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Long COVID-19: A Primer for Cardiovascular Health Professionals, on Behalf of the CCS Rapid Response Team.</ArticleTitle><Pagination><StartPage>1260</StartPage><EndPage>1262</EndPage><MedlinePgn>1260-1262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjca.2021.05.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0828-282X(21)00287-7</ELocationID><Abstract><AbstractText>It is now widely recognized that COVID-19 illness can be associated with significant intermediate and potentially longer-term physical limitations. The term, "long COVID-19" is used to define any patient with persistent symptoms after acute COVID-19 infection (ie, after 4 weeks). It is postulated that cardiac injury might be linked to symptoms that persist after resolution of acute infection, as part of this syndrome. The Canadian Cardiovascular Society Rapid Response Team has generated this document to provide guidance to health care providers on the optimal management of patients with suspected cardiac complications of long COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paterson</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramanathan</LastName><ForeName>Krishnan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Cardiovascular Innovation, Division of Cardiology, University of British Colombia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aurora</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Section of Cardiac Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bewick</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Saint John Regional Hospital, Saint John, New Brunswick, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Chi-Ming</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Division of Cardiology, Department of Medicine, St Michael's Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowan</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Cardiovascular Innovation, Division of Cardiology, University of British Colombia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducharme</LastName><ForeName>Anique</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gin</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Cardiovascular Innovation, Division of Cardiology, University of British Colombia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Trillium Health Partners, Mississauga, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jassal</LastName><ForeName>Davinder S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>St Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kazmi</LastName><ForeName>Mustapha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krahn</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Cardiovascular Innovation, Division of Cardiology, University of British Colombia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamarche</LastName><ForeName>Yoan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Institut de cardiologie de Montr&#xe9;al, Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marelli</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roifman</LastName><ForeName>Idan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruel</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Ottawa Heart Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Gurmeet</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sterns</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Royal Jubilee Hospital, Victoria, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Ricky</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Virani</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Cardiovascular Innovation, Division of Cardiology, University of British Colombia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Kenny K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>IWK Health, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zieroth</LastName><ForeName>Shelley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiac Sciences Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada. Electronic address: szieroth@sbgh.mb.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Cardiol</MedlineTA><NlmUniqueID>8510280</NlmUniqueID><ISSNLinking>0828-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002309" MajorTopicYN="Y">Cardiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017202" MajorTopicYN="N">Myocardial Ischemia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010346" MajorTopicYN="Y">Patient Care Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>Il est d&#xe9;sormais largement reconnu que la COVID-19 peut &#xea;tre associ&#xe9;e &#xe0; d'importantes limitations physiques &#xe0; moyen terme et, potentiellement, &#xe0; plus long terme. Le terme &#xab;&#xa0;COVID-19 longue&#xa0;&#xbb; est utilis&#xe9; pour d&#xe9;crire tout patient pr&#xe9;sentant des sympt&#xf4;mes persistants apr&#xe8;s une infection aigu&#xeb; par le virus de la COVID-19 (soit au-del&#xe0; de quatre&#xa0;semaines). On suppose qu'une atteinte cardiaque pourrait &#xea;tre li&#xe9;e aux sympt&#xf4;mes qui persistent apr&#xe8;s la disparition de l'infection aigu&#xeb;, dans le cadre de ce syndrome. Le Groupe de travail sur la r&#xe9;action rapide &#xe0; la COVID-19 de la Soci&#xe9;t&#xe9; canadienne de cardiologie a produit le pr&#xe9;sent document afin de fournir des conseils aux professionnels de la sant&#xe9; sur la prise en charge optimale des patients chez qui l'on soup&#xe7;onne des complications cardiaques caus&#xe9;es par la COVID-19 longue.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>6</Day><Hour>20</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34090980</ArticleId><ArticleId IdType="pmc">PMC8180343</ArticleId><ArticleId IdType="doi">10.1016/j.cjca.2021.05.011</ArticleId><ArticleId IdType="pii">S0828-282X(21)00287-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prasitlumkum N, Chokesuwattanaskul R, Thongprayoon C. Incidence of myocardial injury in COVID-19-infected patients: a systematic review and meta-analysis. Diseases. 2020;8:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709098</ArticleId><ArticleId IdType="pubmed">33120956</ArticleId></ArticleIdList></Reference><Reference><Citation>Parohan M, Yaghoubi S, Seraji A. Cardiac injury is associated with severe outcome and death in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Eur Heart J Acute Cardiovasc Care. 2020;9:665&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7678334</ArticleId><ArticleId IdType="pubmed">32567326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami R, Sakamoto A, Kawai K. Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77:314&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816957</ArticleId><ArticleId IdType="pubmed">33478655</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha T, Knight DS, Razvi Y. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42:1866&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928984</ArticleId><ArticleId IdType="pubmed">33596594</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>